From the Department of Physiology, Tulane University School of Medicine,
New Orleans, La.
Correspondence to Atsuhiro Ichihara, MD, PhD, Department of Physiology, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112. E-mail ichihara{at}mailhost.tcs.tulane.edu
In vivo studies have suggested that NO exerts an important role in
maintaining renal hemodynamics near the normal range in
kidneys with elevated Ang II levels.7 8 A recent
study showed that urinary excretion of nitrates and nitrites did not
increase but was maintained in rats infused chronically with Ang
II,9 suggesting that NO formation is not
diminished in this model of hypertension. Furthermore, in normotensive
rat kidneys, both afferent and efferent arteriolar responsiveness to
Ang II are modulated by NO.10 Because
preglomerular and postglomerular vascular tone
contribute to renal vascular resistance and glomerular
filtration rate,11 the relative degree to which
NO affects the afferent and efferent arteriolar responsiveness to Ang
II significantly affects renal function. Such interactions may be
further enhanced in hypertensive conditions characterized by elevated
Ang II levels and enhanced microvascular reactivity to Ang II.
The present study was performed to evaluate further the influence
of NO on afferent and efferent arteriolar function in Ang IIinfused
hypertensive rats. We hypothesized that intrarenal NO differentially
influences afferent and efferent arteriolar tone as well as the
microvascular responsiveness to Ang II in Ang IIinduced hypertension.
To test this hypothesis, we used the in vitro blood-perfused
juxtamedullary nephron technique12 13 and
determined the effects of NO blockade and of exogenously supplied NO on
the responsiveness of afferent and efferent arterioles to Ang II in
chronically Ang IIinfused hypertensive rats.
Assessment of Renal Arteriolar Reactivity
The right kidney of the kidney donor was perfused by a cannula advanced
into the right renal artery via the mesenteric artery. The
perfusate was a Tyrode's solution (pH 7.4) containing 5.1%
bovine serum albumin and a mixture of L-amino acids
(Sigma Chemical Co).13 The kidney was excised and
sectioned longitudinally, retaining the papilla intact in the perfused
dorsal two thirds of the organ. Small incisions of the lateral fornices
allowed the papilla to be reflected back, thus exposing the pelvic
mucosa and tissue covering the inner cortical surface. Overlying
connective tissue was removed, and the veins were cut open to reveal
the tubules, glomeruli, and related vasculature of the juxtamedullary
nephrons. The arterial supply of the exposed
microvasculature was isolated by ligating the large branches of renal
artery with fine suture (nylon black monofilament, 100, Vanguard
Surgical System).
After the dissection was completed, the Tyrode's perfusate was
replaced with the reconstituted blood. Perfusion pressure was monitored
by a pressure cannula centered in the perfusion cannula and maintained
at 100 mm Hg during all experimental protocols. Perfusion
pressure was regulated by adjusting the rate of gas inflow into the
blood reservoir. The perfusion chamber was warmed, and the inner
cortical surface was continuously superfused with a warmed (37°C)
Tyrode's solution containing 1% bovine serum albumin.
The tissue was transilluminated on the fixed stage of a Leitz
Laborlux-12 microscope equipped with a 100-W halogen lamp (Leica Inc)
and a water-immersion objective (x40, Zeiss). Video images of the
microvessels were obtained by a Newvicon camera (model NC-67M,
Dage-MTI), passed through a time-date generator (model WJ-810,
Panasonic) and a video contrast enhancer (model 605, Colorado Video
Inc), displayed on a monitor (BWM12A[X], Javelin Electronics), and
recorded on videotape for later analysis (videocassette
recorder HR-VP618U, JVC). Afferent and efferent arteriolar inside
diameters were measured at 12-second intervals with a calibrated
digital image-shearing monitor (Instrumentation for Physiology and
Medicine) that yielded diameter measurements reproducible within
0.5 µm. Afferent arteriolar diameters were measured at sites 75
to 120 µm upstream from the glomerulus, and efferent arteriolar
diameters were measured at sites within 75 µm of the glomerulus,
before the first branch. A minimum 10-minute equilibration period was
allowed before the initiation of each experimental procedure. The
average diameter during the final 1 minute of each 3-minute treatment
period was used for statistical analysis of steady state
responses. All agents were administered by addition to the bathing
solution.
Influences of Endogenous and Exogenous NO on Afferent
and Efferent Arteriolar Vascular Diameters
Roles of Endogenous and Exogenous NO in Afferent and
Efferent Arteriolar Responsiveness to Ang II
Statistical Analysis
Effect of NLA on Afferent and Efferent Arterioles
Effect of SNAP on Afferent and Efferent Arterioles
Effect of NLA on Afferent and Efferent Arteriolar Responses to
Ang II
Figure 3A
Effect of SNAP on Afferent and Efferent Arteriolar Responses to
Ang II
As depicted in Figure 5A
Effect of NLA Combined With SNAP on Afferent and Efferent
Arteriolar Responses to Ang II
Efferent arteriolar diameter averaged 16.1±0.7 µm (n=5) under
control conditions and decreased by 9.2±1.1%, 26.4±2.0%, and
51.1±2.1% during superfusion with 0.1, 1, and 10 nmol/L Ang II,
respectively. After the recovery of efferent arteriolar diameter from
Ang IIinduced vasoconstriction, addition of 100 µmol/L NLA
decreased basal efferent arteriolar diameter by 16.6±0.8% to
13.5±0.6 µm. Addition of 10 µmol/L SNAP increased
efferent arteriolar diameter to 15.8±0.7 µm, which is similar
to the control diameter. Thereafter, efferent arteriolar diameter
decreased by 8.2±0.7%, 23.7±2.3%, and 47.2±2.6% in response to
Ang II. The magnitude of the Ang IImediated decrease in diameter
during the treatment with NLA+SNAP was not different from that observed
under control conditions.
In Ang IIinfused hypertensive rats, NO synthase inhibition with NLA
decreased afferent and efferent arteriolar diameters, and the decrease
in diameter with 10 µmol/L NLA was significantly greater in
afferent than in efferent arterioles. This result suggests that local
NO influence is greater in afferent than in efferent arterioles or that
afferent arteriolar reactivity to vasoconstrictor stimuli is generally
enhanced. However, the latter possibility is unlikely since afferent
arteriolar reactivity to increases in perfusion pressure or to the
calcium ionophore A23187 is not enhanced in Ang IIinfused
hypertension.2 We have previously demonstrated
that NLA decreased afferent and efferent arteriolar diameters to the
same extent in enalaprilat-treated normotensive control
rats14 15 and untreated normotensive control
rats.16 The present results in Ang
IIinfused hypertensive rats indicate that the maximal response of
afferent arterioles to NLA (a 20.9±1.5% decrease) in Ang IIinfused
hypertensive rats is greater than that (a 16.7±0.4% decrease)
observed in untreated normotensive control
rats,16 but that efferent arteriolar maximal
response to NLA (a 16.6±1.6% decrease) in Ang IIinfused
hypertensive rats is similar to that (a 16.6±0.6% decrease) observed
in untreated normotensive control rats.16 In
addition, exogenous NO derived from SNAP increased afferent and
efferent arteriolar diameters, and the increase in diameter with
10 µmol/L SNAP was significantly greater in afferent than
efferent arterioles, suggesting that afferent arterioles have a greater
capacity for NO to vasodilate compared with efferent arterioles. This
relationship between afferent and efferent arteriolar reactivity to
SNAP is similar to that observed previously in enalaprilat-treated
normotensive control rats.15 Therefore, chronic
Ang II infusion does not modify the relatively greater capacity of NO
to modulate microvascular tone in afferent versus efferent
arterioles.
The endogenous NO levels existing in the Ang IIinfused
rats are sufficient to influence the afferent arteriolar reactivity to
Ang II, but the efferent responses are just shifted but not enhanced.
With further increases in NO activity above the endogenous
levels, however, afferent arteriolar reactivity is not influenced
further but efferent arteriolar reactivity to Ang II is significantly
diminished. NO stimulates soluble guanylate cyclase, and
the consequent increase in cyclic GMP can exert a vasodilatory effect
on vascular smooth muscle cells through inhibiting phosphatidylinositol
hydrolysis17 18 19 and Ca2+
release from sarcoplasmic reticulum without involving
Ca2+ influx from extracellular fluid or repletion
of intracellular Ca2+
stores.20 21 Ang IIevoked vasoconstriction of
the efferent arteriole is highly dependent on
Ca2+ release from sarcoplasmic reticulum, while
the afferent arteriolar response is due to Ca2+
influx from extracellular fluid as well as Ca2+
release from intracellular stores.13 22
Accordingly, efferent arteriolar reactivity to Ang II may be much more
sensitive to increased levels of NO compared with the afferent
arteriolar reactivity. Thus, the addition of SNAP to increase local NO
concentrations blunted the Ang II response in efferent arterioles.
However, the endogenous NO activity was apparently not
sufficient to alter the efferent arteriolar reactivity to Ang II. In
afferent arterioles that have maintained NO synthesis activity, Ang II
responsiveness was already modified by the prevailing
endogenously generated NO, and exogenous NO did not provide
any additional effects on Ang II responsiveness, although it did shift
the level of operation. These results suggest a subtle but significant
shift in the quantitative interactions between NO and Ang II
responsiveness in the afferent and efferent arterioles.
Endogenous levels of NO could also modulate afferent
arteriolar responsiveness to Ang II through cyclic GMPindependent
mechanisms. NO can relax vascular smooth muscle by stimulating membrane
hyperpolarization,23 possibly
through inhibition of 20-HETE
production.24 20-HETE is an
endogenous vasoconstrictor of the afferent
arteriole,25 26 and it has been suggested that
this vasoconstriction occurs via 20-HETEmediated inhibition of
vascular smooth muscle K+
channels26 27 and subsequent activation of
voltage-gated Ca2+
channels.25 In addition, afferent arteriolar
responsiveness to Ang II has also been reported to involve activation
of phospholipase A2, resulting in the release of
arachidonic acid from membrane
phospholipids.28 Since 20-HETE is one of the
arachidonic acid metabolites in afferent
arterioles,26 NO inhibition of 20-HETE
production predominantly at the afferent arteriole could be
responsible for modulation of vascular responsiveness to Ang II.
NLA enhancement of afferent arteriolar responsiveness to Ang II was
eliminated when NO levels were fixed by the addition of SNAP. This
result is similar to that observed previously in enalaprilat-treated
normotensive rats10 and suggests that locally
generated NO in afferent arterioles of the hypertensive rat kidney
blunts afferent arteriolar reactivity to Ang II without involving an
actual increase in NO synthesis activity in response to acute Ang II
administration. The results further confirm that the influence of NO on
afferent arteriolar function is maintained during the development of
Ang IIinfused hypertension.
In conclusion, in Ang IIinfused hypertensive rats, the
vasoconstrictor responses to NLA and the vasodilatory responses to SNAP
were greater in afferent than efferent arterioles, indicating that NO
synthesis activity and reactivity are relatively maintained in afferent
arterioles. NO synthesis inhibition with NLA enhanced afferent but not
efferent arteriolar responsiveness to Ang II in Ang IIinfused
hypertensive rats, and the enhancement was abolished by a fixed
concentration of NO. Therefore, NO modulation of Ang II responsiveness
is maintained in afferent but not efferent arterioles. In addition,
SNAP administration blunted efferent but not afferent arteriolar
responsiveness to Ang II, suggesting that the Ang IIevoked efferent
arteriolar vasoconstriction is more sensitive to increased levels of NO
than afferent arterioles. The maintained NO-dependent tone and function
in afferent arterioles may contribute to maintaining renal
hemodynamics during the development of Ang
IIdependent hypertension.
Received December 9, 1997;
first decision January 6, 1998;
accepted January 13, 1998.
2.
Ichihara A, Inscho EW, Imig JD, Michel RE, Navar LG.
Role of renal nerves in afferent arteriolar reactivity in
angiotensin-induced hypertension. Hypertension. 1997;29:442449.
3.
Martinez-Maldonado M. Pathophysiology of renovascular
hypertension. Hypertension. 1991;17:707719.
4.
Himmelstein SI, Klotman PE. The role of
thromboxane in two-kidney, one-clip Goldblatt hypertension
in rats. Am J Physiol. 1989;257:F190F196.
5.
Wang C, Zou L, Navar LG. Renal response to AT1
blockade in angiotensin II-induced hypertensive rats.
J Am Soc Nephrol. 1997;8:535542.[Abstract]
6.
Wang DH, Du Y, Yao A, Hu Z. Regulation of type 1
angiotensin II receptor and its subtype gene expression in
kidney by sodium loading and angiotensin II infusion.
J Hypertens. 1996;14:14091415.[Medline]
[Order article via Infotrieve]
7.
Sigmon DH, Beierwaltes WH. Renal nitric oxide and
angiotensin II interaction in renovascular hypertension.
Hypertension. 1993;22:237242.
8.
Beierwaltes WH, Potter DL, Carretero OA, Sigmon DH.
Nitric oxide synthesis inhibition blocks reversal of two-kidney, one
clip renovascular hypertension after unclipping.
Hypertension. 1995;25:174179.
9.
Deng X, Welch WJ, Wilcox CS. Role of nitric oxide in
short-term and prolonged effects of angiotensin II on renal
hemodynamics. Hypertension. 1996;27:11731179.
10.
Ikenaga H, Fallet RW, Carmines PK. Basal nitric oxide
production curtails arteriolar vasoconstrictor responses to ANG
II in rat kidney. Am J Physiol. 1996;271:F365F373.
11.
Navar LG, Inscho EW, Majid DSA, Imig JD,
Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal
microcirculation. Physiol Rev. 1996;76:425536.
12.
Casellas D, Navar LG. In vitro perfusion of
juxtamedullary nephrons in rats. Am J Physiol. 1984;246:F349F358.
13.
Carmines PK, Navar LG. Disparate effects of Ca channel
blockade on afferent and efferent arteriolar responses to ANGII.
Am J Physiol. 1989;256:F1015F1020.
14.
Ohishi K, Carmines PK, Inscho EW, Navar LG.
EDRF-angiotensin II interactions in rat juxtamedullary
afferent and efferent arterioles. Am J Physiol. 1992;263:F900F906.
15.
Ichihara A, Inscho EW, Navar LG. Influence of nitric
oxide levels on afferent arteriolar responses to
angiotensin II. J Am Soc Nephrol. 1996;7:1563. Abstract.
16.
Ichihara A, Inscho EW, Imig JD, Navar LG.
Neuronal nitric oxide synthase modulates rat renal microvascular
function. Am J Physiol. 1998. In press.
17.
Rapaport R. Cyclic guanosine monophosphate inhibition
of contraction may be mediated through inhibition of
phosphoinositide hydrolysis in rat aorta. Circ
Res. 1986;18:407410.
18.
Lang D, Lewis MJ.
Endothelium-derived relaxing factor inhibits the
formation of inositol trisphosphate by rabbit aorta. J
Physiol. 1989;411:4552.
19.
Hirata M, Kohse KP, Chang C, Tkebe T, Murad F.
Mechanisms of cyclic GMP inhibition of inositol phosphate formation in
rat aorta segments and cultured bovine aortic smooth muscle cells.
J Biol Chem. 1990;265:12681273.
20.
Kannan MS, Prakash YS, Johnson DE, Sieck GC. Nitric
oxide inhibits calcium release from sarcoplasmic reticulum of porcine
tracheal smooth muscle cells. Am J Physiol. 1997;272:L1L7.
21.
Yuan X, Bright RT, Aldinger M, Rubin LJ. Nitric oxide
inhibits serotonin-induced calcium release in
pulmonary artery smooth muscle cells. Am J
Physiol. 1997;272:L44L50.[Abstract]
22.
Inscho EW, Imig JD, Cook AK. Afferent and efferent
arteriolar vasoconstriction to angiotensin II and
norepinephrine involves release of
Ca2+ from intracellular stores.
Hypertension. 1997;29:222227.
23.
Tare M, Parkington HC, Coleman HA, Neild TO, Dusting
GJ. Hyperpolarization and relaxation of
arterial smooth muscle caused by nitric oxide derived from
the endothelium. Nature. 1990;346:6971.[Medline]
[Order article via Infotrieve]
24.
Alonso-Galicia M, Drummond HA, Reddy KK, Falck JR,
Roman RJ. Inhibition of 20-HETE production contributes to
the vascular responses to nitric oxide. Hypertension. 1997;29:320325.
25.
Ma Y, Gebremedhin D, Schwartzman ML, Falck JR, Clark
JE, Masters BS, Harder DR, Roman RJ.
20-Hydroxyeicosatetraenoic acid is an
endogenous vasoconstrictor of canine renal arcuate
arteries. Circ Res. 1993;72:126136.
26.
Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman
RJ. Formation and actions of
20-hydroxyeicosatetraenoic acid in the
renal microcirculation. Am J Physiol. 1996;270:R217R227.
27.
Zou A, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D,
Harder DR, Roman RJ. 20-HETE is an endogenous
inhibitor of the large-conductance
Ca2+-activated K+ channel in renal
arterioles. Am J Physiol. 1996;270:R228R237.
28.
Imig JD, Deichmann PC. Afferent arteriolar responses to
ANG II involve activation of PLA2 and modulation by
lipoxygenase and P-450 pathways. Am J
Physiol. 1997;273:F274F282.
© 1998 American Heart Association, Inc.
Scientific Contributions
Interactive Nitric OxideAngiotensin II Influences on Renal Microcirculation in Angiotensin IIInduced Hypertension
![]()
Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References
AbstractThe present study was
conducted to determine the contribution of nitric oxide to
angiotensin II (Ang II) reactivity of afferent and efferent
arterioles from Ang IIinfused hypertensive rats. Experiments were
performed in vitro with the blood-perfused juxtamedullary nephron
technique in kidneys harvested from hypertensive Sprague-Dawley rats
(181±1 mm Hg) that had received 60 ng/min Ang II subcutaneously
for 13 days. Superfusion with 0.1, 1, and 10 nmol/L Ang II reduced
afferent arteriolar diameter (18.1±0.6 µm; n=12) by
10.0±0.7%, 28.1±1.7%, and 52.8±1.9%, respectively, and efferent
arteriolar diameter (17.2±1.4 µm; n=8) decreased by 9.3±0.7%,
27.0±1.2%, and 50.4±1.6%, respectively. Nitric oxide synthase
inhibition with 100 µmol/L
N
-nitro-L-arginine (NLA)
reduced resting afferent and efferent arteriolar diameters to 14.7±0.4
and 14.3±1.2 µm, respectively, and enhanced afferent but not
efferent arteriolar reactivity to Ang II. The enhanced afferent
arteriolar reactivity to Ang II was eliminated by addition of the
nitric oxide donor
S-nitroso-N-acetylpenicillamine (SNAP,
10 µmol/L), which reversed the NLA-induced decrease in diameter.
Addition of 10 µmol/L SNAP, without NLA, blunted efferent but
not afferent arteriolar reactivity to Ang II. Afferent (n=7) and
efferent arteriolar diameters (n=6) decreased by 48.5±2.2% and
41.0±1.9%, respectively, in response to 10 nmol/L Ang II. These
results suggest that in this model of hypertension, maintained nitric
oxide production in afferent arterioles counteracts the
enhanced afferent arteriolar reactivity that occurs in Ang
IIinduced hypertension.
Key Words: rats kidney arterioles nitric oxide angiotensin II
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
Rats infused with
initially subpressor doses of Ang II slowly develop progressive
hypertension similar to that observed in two-kidney, one clip Goldblatt
hypertension.1 In these models of hypertension,
renal Ang II levels are increased and afferent arteriolar reactivity to
Ang II is enhanced.2 Because afferent arterioles
are the segment that accounts for the major fraction of
preglomerular vascular resistance, an alteration in the
vascular reactivity of this segment may exert a strong influence on the
regulation of renal blood flow and glomerular filtration
rate. Nevertheless, in the nonclipped kidney of two-kidney, one clip
Goldblatt hypertensive animals and in kidneys of Ang IIinfused
hypertensive rats, renal blood flow and glomerular
filtration rate are either not reduced or only slightly
diminished.3 4 5 Although decreases in the number
of intrarenal Ang II receptors might occur as a consequence of the
increased renal Ang II levels,6 afferent
arteriolar responsiveness to Ang II is actually enhanced in this model
of hypertension.2 Therefore, the mechanisms
responsible for the maintenance of near normal renal blood flow
and glomerular filtration rate in this model of
hypertension remain undetermined.
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
Preparation of Animals
Male Sprague-Dawley rats (Charles River Labs, Wilmington, Mass)
were housed in wire cages and maintained in a temperature-controlled
room that was regulated on a 12/12-hour light-dark cycle. Rats had free
access to water and standard rat chow (Ralston-Purina). All
experimental protocols were approved by the Tulane University Animal
Care and Use Committee. Rats (175 to 200 g body wt) were
anesthetized with sodium pentobarbital (50 mg/kg IP). An
osmotic minipump (model 2002, Alza Corp) was implanted subcutaneously
at the dorsum of the neck. Ang IIinfused rats received Ang II
(Novabiochem) at a rate of 60 ng/min for a period of 13 days.
Systolic blood pressure was measured every 3 days in conscious
rats by tail-cuff plethysmography (model 52-0338; Harvard
Apparatus).
Afferent and efferent arteriolar reactivity were assessed with
the in vitro blood-perfused juxtamedullary nephron technique combined
with videomicroscopy, as previously
described.12 13 Experiments were performed on day
13 after minipump implantation. Each experiment used two rats from the
same treatment group with one rat serving as the blood donor and the
second rat as the kidney donor. Rats were anesthetized with
sodium pentobarbital (50 mg/kg IP), and a cannula was inserted into the
left carotid artery of the blood donor. Donor blood was collected into
a heparinized (500 U) syringe via the carotid arterial
cannula and centrifuged to separate the plasma and cellular
fractions. The buffy coat was removed and discarded. Plasma oncotic
pressure was adjusted to 18 mm Hg by the addition of bovine serum
albumin (Sigma Chemical Co). After sequential passage of the
plasma through 5- and 0.22-µm filters (Gelman Sciences), erythrocytes
were added to achieve a hematocrit of 33%. This reconstituted blood
was passed through a 5-µm nylon mesh and thereafter stirred
continuously in a closed reservoir that was pressurized with a 95%
O2/5% CO2 gas mixture.
The contribution of endogenous NO production
to microvascular diameter was determined in Ang IIinfused
hypertensive rats. Afferent and efferent arteriolar diameters were
measured under control conditions and during exposure to increasing
concentrations (1 to 1000 µmol/L) of the NO synthase
inhibitor NLA (Aldrich Chemical Co). In a second series
of experiments, we examined the effect of exogenously administered NO
on microvascular diameter by measuring afferent and efferent arteriolar
diameters before and during exposure to the NO donor SNAP (Sigma
Chemical Co). Microvascular diameter responses were determined under
control conditions and during exposure to increasing concentrations
(0.1 to 100 µmol/L) of SNAP.
The role of endogenous NO production on Ang
IImediated microvascular vasoconstriction was determined by
evaluating the decreases in afferent and efferent arteriolar diameters
in response to 0.1, 1, and 10 nmol/L Ang II (Calbiochem-Novabiochem
Corp) before and during the addition of 100 µmol/L NLA. A second
series of experiments was performed to determine the effect of
exogenously administered NO on the microvascular response to Ang II.
Afferent and efferent arteriolar diameters were measured in response to
0.1, 1, and 10 nmol/L Ang II before and during the addition of 10
µmol/L SNAP. Finally, experiments were performed to determine whether
Ang II stimulation of NO synthesis contributes to
endogenous NO modulation of afferent and efferent
arteriolar reactivity to Ang II. In these experiments, ambient NO
concentration was fixed at a constant level with 10 µmol/L SNAP,
and afferent and efferent arteriolar reactivity to the same
concentrations of Ang II were examined in the presence and absence of
100 µmol/L NLA. We previously determined the reproducibility of
arteriolar responses to repeated Ang II administration and found no
significant difference in the responses between the first and second
treatments.2
Differences in mean values between treatment groups were
evaluated with a two-way ANOVA for repeated measures. Comparisons
between afferent and efferent arteriolar diameter responses to
different treatments and comparisons of percent changes in the Ang II
response between treatments were made by a Fisher's protected
least-squares difference test followed by Bonferroni's correction for
multiple comparisons. Comparisons of the Ang II response expressed in
micrometers between treatments were made by means of a
paired t test with Bonferroni's correction for multiple
comparisons. A value of P<0.05 was considered significant.
Data are presented as mean±SEM.
![]()
Results
Top
Abstract
Introduction
Methods
Results
Discussion
References
Chronic Ang II infusion significantly increased systolic
blood pressure from 121±1 mm Hg on day 0 to 181±1 mm Hg
on day 13 (n=52). The increase in systolic blood pressure in
the Ang IIinfused rats is similar to that observed previously and is
greater than that measured previously in the saline vehicleinfused
control rats.2
The dose-response effects of NLA on afferent and efferent
arteriolar diameters were determined in Ang IIinfused hypertensive
rats. Control diameter of the afferent arteriole averaged
18.7±0.7 µm (n=6). As illustrated in Figure 1A
, superfusion with 1, 10, 100, and
1000 µmol/L NLA reduced afferent arteriolar diameter by
5.9±0.6%, 13.2±0.3%, 20.9±1.5%, and 20.5±1.6%, respectively.
Efferent arteriolar diameter averaged 17.6±0.4 µm (n=6) under
control conditions and decreased by 4.4±0.4%, 9.7±1.1%,
16.6±1.6%, and 16.3±1.5%, respectively, in response to the same
concentrations of NLA. The afferent arteriolar vasoconstriction to
10 µmol/L NLA was significantly greater than the vasoconstrictor
response of efferent arterioles.

View larger version (17K):
[in a new window]
Figure 1. Effects of NLA (A) and SNAP (B) on afferent (
)
and efferent (
) arteriolar diameters. Data are expressed as percent
change of the control diameter for Ang IIinfused rats.
*P<0.05 vs control period,
P<0.05 vs
efferent diameter.
The dose-response effects of SNAP on afferent and efferent
arteriolar diameters are shown in Figure 1B
. Superfusion with 0.1, 1,
10, and 100 µmol/L SNAP increased afferent arteriolar diameter
from a control of 19.0±0.8 µm (n=6) by -0.2±0.6%,
5.3±0.2%, 12.0±1.2%, and 8.2±0.9%, respectively. Efferent
arteriolar diameters averaged 17.9±1.1 µm (n=6), and the same
concentrations of SNAP increased efferent arteriolar diameters by
0.1±0.2%, 3.6±0.7%, 6.4±0.8%, and 6.6±0.7%. The afferent
arteriolar vasodilation to 10 µmol/L SNAP was significantly
greater than efferent arteriolar response.
The effects of endogenously formed NO on afferent and
efferent arteriolar reactivity to Ang II are depicted in Figures 2
and 3
. Afferent arteriolar diameter averaged
18.1±0.6 µm (n=12) under control conditions and decreased by
10.0±0.7%, 28.1±1.7%, and 52.8±1.9% during superfusion with 0.1,
1, and 10 nmol/L Ang II, respectively. After the recovery of afferent
arteriolar diameter from Ang IIinduced vasoconstriction, NO synthesis
inhibition with 100 µmol/L NLA decreased basal afferent
arteriolar diameter by 18.4±1.2% to 14.7±0.4 µm. In the
presence of NLA, afferent arteriolar responsiveness to Ang II was
significantly enhanced (Figure 2B
). During addition of NLA, afferent
arteriolar diameters decreased by 19.8±2.0%, 48.1±2.8%, and
79.2±3.8% in response to the same Ang II concentrations. At all
concentrations of Ang II, the percent decreases were significantly
greater than those observed before addition of NLA (Figure 2B
).

View larger version (21K):
[in a new window]
Figure 2. Afferent arteriolar responses to Ang II before
(
) and during (
) NO synthase inhibition with 100 µmol/L
NLA in Ang IIinfused rats. Data are expressed in
micrometers (A) and as percent change of the control
diameter (B). *P<0.05 vs control period,
P<0.05 vs before NLA administration.

View larger version (19K):
[in a new window]
Figure 3. Efferent arteriolar responses to Ang II before
(
) and during (
) NO synthase inhibition with 100 µmol/L
NLA in Ang IIinfused rats. Data are expressed in
micrometers (A) and as percent change of the control
diameter (B). *P<0.05 vs control period,
P<0.05 vs before NLA administration.
illustrates that efferent
arteriolar diameter averaged 17.2±1.4 µm (n=8) under control
conditions and decreased by 9.3±0.7%, 27.0±1.2%, and 50.4±1.6%
during superfusion with 0.1, 1, and 10 nmol/L Ang II, respectively.
After the recovery of efferent arteriolar diameter, NLA (100
µmol/L) decreased basal efferent arteriolar diameter by 16.8±0.5%
to 14.3±1.2 µm. However, NLA did not influence efferent
arteriolar responsiveness to Ang II, and the relative efferent
arteriolar diameters were similarly reduced to 9.3±0.8%, 28.1±1.4%,
and 50.3±2.4% in response to the same Ang II concentrations (Figure 3B
).
To examine whether the NO donor SNAP attenuates renal arteriolar
responsiveness to Ang II, afferent and efferent arteriolar diameter
responses to Ang II were examined before and during SNAP administration
in Ang IIinfused hypertensive rats. Figure 4A
demonstrates that afferent arteriolar
diameter averaged 18.9±0.4 µm (n=7) under control conditions
and decreased by 12.5±1.5%, 25.1±1.3%, and 51.2±0.9% during
superfusion with 0.1, 1, and 10 nmol/L Ang II, respectively. The
addition of 10 µmol/L SNAP increased resting afferent arteriolar
diameters by 11.1±1.5% to 21.0±0.6 µm, but the relative
constrictor responses to Ang II were not significantly altered. In the
presence of SNAP, afferent arteriolar diameters decreased by
11.7±1.7%, 22.6±1.9%, and 48.5±2.2% in response to 0.1, 1, and 10
nmol/L Ang II (Figure 4B
).

View larger version (20K):
[in a new window]
Figure 4. Afferent arteriolar responses to Ang II before
(
) and during (
) addition of NO with 10 µmol/L SNAP in Ang
IIinfused rats. Data are expressed in micrometers (A) and
as percent change of the control diameter (B). *P<0.05
vs control period,
P<0.05 vs before SNAP
administration.
, efferent
arteriolar diameter averaged 16.4±0.8 µm (n=6) and decreased by
9.8±0.4%, 17.7±0.6%, and 53.3±0.9% during superfusion with 0.1,
1, and 10 nmol/L Ang II, respectively. The addition of 10 µmol/L
SNAP significantly increased resting efferent arteriolar diameter by
5.1±0.7% to 17.2±0.9 µm, and this increase was similar to
that observed in the series shown in Figure 1B
. The addition of 10
µmol/L SNAP significantly blunted the vasoconstrictor response to Ang
II. In the presence of SNAP, efferent arteriolar diameter decreased by
7.6±0.5%, 11.4±1.0%, and 41.0±1.9% during superfusion with the
same concentrations of Ang II, and the percent decreases were
significantly smaller than those observed under control conditions
(Figure 5B
).

View larger version (20K):
[in a new window]
Figure 5. Efferent arteriolar responses to Ang II before
(
) and during (
) addition of NO with 10 µmol/L SNAP in Ang
IIinfused rats. Data are expressed in micrometers (A) and
as percent change of the control diameter (B). *P<0.05
vs control period,
P<0.05 vs before SNAP
administration.
Afferent arteriolar diameter averaged 17.6±0.9 µm (n=6)
under control conditions and decreased by 9.0±0.6%, 27.2±1.5%, and
48.6±2.8% in response to 0.1, 1, and 10 nmol/L Ang II, respectively.
After the recovery of afferent arteriolar diameter from Ang IIinduced
vasoconstriction, addition of 100 µmol/L NLA significantly
decreased basal afferent arteriolar diameter by 19.8±0.7% to
14.1±0.7 µm. Then 10 µmol/L SNAP increased afferent
arteriolar diameter to 17.3±0.8 µm. Thus, afferent diameter
during combined treatment with SNAP+NLA was similar to the control
diameter. Thereafter, afferent arteriolar diameter declined by
9.3±0.9%, 23.8±2.9%, and 40.5±3.2% in response to 0.1, 1, and 10
nmol/L Ang II, which was similar to that observed under control
conditions.
![]()
Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References
In normotensive rats, intrarenal NO regulates afferent and
efferent arteriolar tone14 and modulates both
afferent and efferent arteriolar responsiveness to Ang II without
involving specific acute enhancement of Ang IImediated NO
production.10 In Ang IIdependent
hypertension, renal blood flow is maintained during the early phase of
developing hypertension3 4 5 despite increased
intrarenal Ang II levels and enhanced afferent arteriolar reactivity to
Ang II.2 NO has been suggested as one of the
factors counteracting the elevated Ang IIdependent influence. The
present study was conducted to determine the influence of NO on
afferent and efferent arteriolar tone and the effect of NO on
microvascular responsiveness to Ang II in Ang IIinfused hypertensive
rats.
![]()
Selected Abbreviations and Acronyms
Ang II
=
angiotensin II
20-HETE
=
20-hydroxyeicosatetraenoic acid
NLA
=
N
-nitro-L-arginine
NO
=
nitric oxide
SNAP
=
S-nitroso-N-acetylpenicillamine
![]()
Acknowledgments
This study was supported by a J. Walter Libby Fellowship Grant
from the American Heart Association, Louisiana Affiliate, Inc (Dr
Ichihara) and grant HL-26371 from the National Institutes of Health. Dr
Inscho is an Established Investigator of the American Heart
Association. The authors thank Anthony K. Cook for technical
assistance.
![]()
References
Top
Abstract
Introduction
Methods
Results
Discussion
References
1.
VonThun AM, Vari RC, El-Dahr SS, Navar LG.
Augmentation of intrarenal angiotensin II levels by chronic
angiotensin II infusion. Am J Physiol. 1994;266:F120F128.
This article has been cited by other articles:
![]() |
M. Hultstrom, F. Helle, and B. M. Iversen AT1 receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats Am J Physiol Renal Physiol, July 1, 2009; 297(1): F163 - F168. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Helle, M. Hultstrom, T. Skogstrand, F. Palm, and B. M. Iversen Angiotensin II-induced contraction is attenuated by nitric oxide in afferent arterioles from the nonclipped kidney in 2K1C Am J Physiol Renal Physiol, January 1, 2009; 296(1): F78 - F86. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stegbauer, Y. Kuczka, O. Vonend, I. Quack, L. Sellin, A. Patzak, A. Steege, K. Langnaese, and L. C. Rump Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R421 - R428. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-G. Feng and L. G. Navar Nitric oxide synthase inhibition activates L- and T-type Ca2+ channels in afferent and efferent arterioles Am J Physiol Renal Physiol, April 1, 2006; 290(4): F873 - F879. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Welch, J. Blau, H. Xie, T. Chabrashvili, and C. S. Wilcox Angiotensin-induced defects in renal oxygenation: role of oxidative stress Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H22 - H28. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cervenka, H. J. Kramer, J. Maly, and J. Heller Role of nNOS in Regulation of Renal Function in Angiotensin II-Induced Hypertension Hypertension, August 1, 2001; 38(2): 280 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. PATZAK, R. MROWKA, E. STORCH, B. HOCHER, and P. B. PERSSON Interaction of Angiotensin II and Nitric Oxide in Isolated Perfused Afferent Arterioles of Mice J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1122 - 1127. [Abstract] [Full Text] |
||||
![]() |
A. Ichihara, M. Hayashi, N. Hirota, and T. Saruta Superoxide Inhibits Neuronal Nitric Oxide Synthase Influences on Afferent Arterioles in Spontaneously Hypertensive Rats Hypertension, February 1, 2001; 37(2): 630 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nishiyama, T. Fukui, Y. Fujisawa, M. Rahman, R.-X. Tian, S. Kimura, and Y. Abe Systemic and Regional Hemodynamic Responses to Tempol in Angiotensin II-Infused Hypertensive Rats Hypertension, January 1, 2001; 37(1): 77 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. ICHIHARA, M. HAYASHI, L. G. NAVAR, and T. SARUTA Inducible Nitric Oxide Synthase Attenuates Endothelium-Dependent Renal Microvascular Vasodilation J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1807 - 1812. [Abstract] [Full Text] |
||||
![]() |
A. ROCZNIAK, J. N. FRYER, D. Z. LEVINE, and K. D. BURNS Downregulation of Neuronal Nitric Oxide Synthase in the Rat Remnant Kidney J. Am. Soc. Nephrol., April 1, 1999; 10(4): 704 - 713. [Abstract] [Full Text] |
||||
![]() |
A. Ichihara, J. D. Imig, and L. G. Navar Neuronal Nitric Oxide Synthase-Dependent Afferent Arteriolar Function in Angiotensin II-Induced Hypertension Hypertension, January 1, 1999; 33(1): 462 - 466. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |